Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors
Francesco Facchinetti, Antoine Hollebecque, Rastislav Bahleda, et al.
Clinical Cancer Research (2019) Vol. 26, Iss. 4, pp. 764-774
Open Access | Times Cited: 105

Showing 1-25 of 105 citing articles:

Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
Pharmacological Research (2019) Vol. 152, pp. 104609-104609
Closed Access | Times Cited: 476
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 174
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies
Vivek Subbiah, Nicholas Iannotti, Martin Gutierrez, et al.
Annals of Oncology (2022) Vol. 33, Iss. 5, pp. 522-533
Open Access | Times Cited: 148
Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Young Kwang Chae, Fangxin Hong, Christos Vaklavas, et al.
Journal of Clinical Oncology (2020) Vol. 38, Iss. 21, pp. 2407-2417
Open Access | Times Cited: 146
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 144
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Anuhya Kommalapati, Sri Harsha Tella, Mitesh J. Borad, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2968-2968
Open Access | Times Cited: 118
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder
Robert Roskoski
Pharmacological Research (2019) Vol. 151, pp. 104567-104567
Closed Access | Times Cited: 116
Targetable Molecular Alterations in the Treatment of Biliary Tract Cancers: An Overview of the Available Treatments
Marine Valéry, Damien Vasseur, Francesco Fachinetti, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4446-4446
Open Access | Times Cited: 27
Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
Zhichao Tian, Xiaohui Niu, Weitao Yao
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 70
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor
Liangxing Wu, Colin Zhang, Chunhong He, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 15, pp. 10666-10679
Closed Access | Times Cited: 55
Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)
Liping Hu, Mengmeng Fan, Shengmin Shi, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113963-113963
Closed Access | Times Cited: 51
Ex vivo drug testing of patient-derived lung organoids to predict treatment responses for personalized medicine
Josephine A. Taverna, Chia‐Nung Hung, Madison Williams, et al.
Lung Cancer (2024) Vol. 190, pp. 107533-107533
Open Access | Times Cited: 8
Novel benzenesulfonamides as dual VEGFR2/FGFR1 inhibitors targeting breast cancer: Design, synthesis, anticancer activity and in silico studies
Rasha M. Hassan, Islam H. Ali, Ahmed M. El Kerdawy, et al.
Bioorganic Chemistry (2024) Vol. 152, pp. 107728-107728
Closed Access | Times Cited: 7
FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response
Olga Bogatyrova, Johanna Sofia Margareta Mattsson, Edith Ross, et al.
European Journal of Cancer (2021) Vol. 151, pp. 136-149
Open Access | Times Cited: 38
FGF9/FGFR1 promotes cell proliferation, epithelial-mesenchymal transition, M2 macrophage infiltration and liver metastasis of lung cancer
Ming‐Min Chang, Su-Zhen Wu, Shang‐Hsun Yang, et al.
Translational Oncology (2021) Vol. 14, Iss. 11, pp. 101208-101208
Open Access | Times Cited: 35
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived models
Nicole J. Chew, Terry C.C. Lim Kam Sian, Elizabeth V. Nguyen, et al.
Breast Cancer Research (2021) Vol. 23, Iss. 1
Open Access | Times Cited: 33
Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
Qianmeng Lin, Xiaojuan Chen, Lingzhi Qu, et al.
Communications Chemistry (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 27
Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments
Anderley Gordon, Edwina Johnston, David K. Lau, et al.
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1183-1196
Open Access | Times Cited: 26
FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?
Csongor György Lengyel, Sadaqat Hussain, Andreas Seeber, et al.
Life (2022) Vol. 12, Iss. 1, pp. 81-81
Open Access | Times Cited: 23
3D-QSAR, docking and molecular dynamics simulations of novel Pyrazolo-pyridazinone derivatives as covalent inhibitors of FGFR1: a scientific approach for possible anticancer agents
Shafaq Hamza, Abira Abid, A. Khanum, et al.
Journal of Biomolecular Structure and Dynamics (2023) Vol. 42, Iss. 5, pp. 2242-2256
Closed Access | Times Cited: 15
An FGFR/AKT/SOX2 Signaling Axis Controls Pancreatic Cancer Stemness
Mei-Yu Quan, Qiang Guo, Jiayu Liu, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 39
Design, Synthesis, and Biological Evaluation of Aminoindazole Derivatives as Highly Selective Covalent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR4
Min Shao, Xiaojuan Chen, Fang Yang, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 6, pp. 5113-5133
Closed Access | Times Cited: 22
FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma
Zhanchao Tao, Yue Cui, Xilong Xu, et al.
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 40
Open Access | Times Cited: 20
Targeting the FGF/FGFR axis and its co-alteration allies
Yuji Uehara, Sadakatsu Ikeda, K.H. Kim, et al.
ESMO Open (2022) Vol. 7, Iss. 6, pp. 100647-100647
Open Access | Times Cited: 19
Discovery of potential FGFR3 inhibitors via QSAR, pharmacophore modeling, virtual screening and molecular docking studies against bladder cancer
Mahmoud Ganji, Shohreh Bakhshi, Alireza Shoari, et al.
Journal of Translational Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top